Flax Pond Capital LLC Invests $1.23 Million in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Flax Pond Capital LLC acquired a new position in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 173,633 shares of the company’s stock, valued at approximately $1,229,000. Flax Pond Capital LLC owned about 0.25% of Bicycle Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of BCYC. Assetmark Inc. grew its position in shares of Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after buying an additional 1,552 shares during the last quarter. Clearstead Advisors LLC increased its stake in shares of Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after buying an additional 3,262 shares during the period. Brooklyn Investment Group bought a new position in shares of Bicycle Therapeutics during the fourth quarter worth about $69,000. Ausdal Financial Partners Inc. bought a new position in shares of Bicycle Therapeutics during the second quarter worth about $70,000. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new position in shares of Bicycle Therapeutics in the fourth quarter worth approximately $71,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 5,967 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total transaction of $29,297.97. Following the transaction, the chief executive officer owned 613,029 shares in the company, valued at $3,009,972.39. The trade was a 0.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 9,992 shares of company stock valued at $49,363. Insiders own 22.90% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $4.00 on Friday. The company has a market cap of $278.89 million, a P/E ratio of -1.27 and a beta of 1.54. The stock has a 50 day simple moving average of $4.60 and a two-hundred day simple moving average of $5.52. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $3.95 and a fifty-two week high of $9.18.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $7.50 million. Bicycle Therapeutics had a negative net margin of 344.95% and a negative return on equity of 35.74%. On average, research analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -1.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BCYC. Truist Financial set a $8.00 target price on Bicycle Therapeutics in a report on Tuesday, March 17th. Jefferies Financial Group restated a “buy” rating and issued a $12.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, April 30th. Citizens Jmp reduced their price objective on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Wednesday, March 18th. Citigroup reaffirmed a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Friday, April 10th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bicycle Therapeutics currently has an average rating of “Hold” and an average target price of $14.00.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.